螺内酯与阿米洛利治疗难治性高血压:一项随机临床试验
该研究在韩国14个中心前瞻性纳入118例经4周固定剂量三联降压药后家庭收缩压仍≥130 mm Hg的难治性高血压患者,1:1随机接受螺内酯12.5 mg/d(n=60)或阿米洛利5 mg/d(n=58),必要时加量。第12周家庭收缩压降幅组间差异为-0.68 mm Hg(90%CI,-3.50至2.14),阿米洛利对螺内酯非劣效。
要点
- 阿米洛利5 mg/d在降低家庭收缩压方面对螺内酯12.5 mg/d非劣效(组间差异-0.68 mm Hg;90%CI,-3.50至2.14)。
- 第12周家庭收缩压<130 mm Hg达标率:阿米洛利组66.1%,螺内酯组55.2%;诊室达标率分别为57.1%和60.3%,两组无差异。
- 阿米洛利组发生1例因高钾血症停药,两组均无男性乳房发育症。
核心结论
- 阿米洛利在降低家庭收缩压方面对螺内酯非劣效,提示其可能成为难治性高血压的有效替代治疗。
研究设计与样本
- 前瞻性、开放标签、盲法终点随机临床试验,在韩国14个中心开展。
- 2020年11月16日至2024年2月29日纳入118例经4周固定剂量三联药物(血管紧张素受体阻滞剂、钙通道阻滞剂和噻嗪类)导入后家庭收缩压≥130 mm Hg的难治性高血压患者。
- 患者按1:1随机接受螺内酯12.5 mg/d(n=60)或阿米洛利5 mg/d(n=58);4周后若家庭收缩压仍≥130 mm Hg且血钾<5.0 mmol/L,则分别加量至25 mg/d和10 mg/d。
主要发现
- 研究人群中位年龄55岁,男性占70%。
- 阿米洛利组和螺内酯组基线平均家庭收缩压分别为141.5(SD,7.9)mm Hg和142.3(SD,8.5)mm Hg。
- 第12周时,阿米洛利组和螺内酯组家庭收缩压较基线分别变化-13.6(SD,8.6)mm Hg和-14.7(SD,11.0)mm Hg,组间变化差异为-0.68 mm Hg(90%CI,-3.50至2.14 mm Hg),阿米洛利对螺内酯非劣效。
- 第12周家庭收缩压<130 mm Hg达标率在阿米洛利组和螺内酯组分别为66.1%和55.2%,诊室收缩压<130 mm Hg达标率分别为57.1%和60.3%,两组间无差异。
- 阿米洛利组发生1例因高钾血症相关停药,两组均无男性乳房发育症病例。
关键数值与推荐
- 主要终点为非劣效检验,非劣效界值为置信区间下限-4.4 mm Hg。
- 阿米洛利组与螺内酯组第12周家庭收缩压变化组间差异为-0.68 mm Hg(90%CI,-3.50至2.14 mm Hg)。
临床怎么用
- 作者认为,阿米洛利在降低家庭收缩压方面对螺内酯非劣效,提示其可能成为难治性高血压的有效替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension. OBJECTIVE: To determine whether amiloride is noninferior to spironolactone in reducing home-measured systolic blood pressure (SBP) in patients with resistant hypertension. DESIGN, SETTING, AND PARTICIPANTS: Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled. INTERVENTION: Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively. MAIN OUTCOMES AND MEASURES: The primary end point was the between-group difference in home SBP change at week 12, with a noninferiority margin of -4.4 mm Hg for the lower bound of the confidence interval. Secondary end points included achievement rates of home- and office-measured SBP of less than 130 mm Hg. RESULTS: The median age of the study population was 55 years, with 70% male. There were no differences between groups in demographic characteristics other than use of α-blockers (8.6% in the amiloride group and 0% in the spironolactone group). The mean baseline home SBPs were 141.5 (SD, 7.9) mm Hg and 142.3 (SD, 8.5) mm Hg in the amiloride and spironolactone groups, respectively. At week 12, mean home SBP measurements were changed from baseline by -13.6 (SD, 8.6) mm Hg and -14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, -0.68 mm Hg; 90% CI, -3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone. Home-measured achievement rates of SBP less than 130 mm Hg in the amiloride and spironolactone groups were 66.1% and 55.2%, respectively, and office-measured achievement rates of SBP less than 130 mm Hg were 57.1% and 60.3%, respectively, with no difference between the 2 groups. One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group. CONCLUSIONS AND RELEVANCE: Amiloride was noninferior to spironolactone in lowering home SBP, suggesting that it could be an effective alternative for treatment of resistant hypertension. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04331691.
引用
- Lee CJ, Ihm SH, Shin DH, et al. Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial. JAMA. 2025. PMID: 40366680. doi:10.1001/jama.2025.5129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。